Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ayala Pharmaceuticals, Inc.ADXS · Entity 93434 | Director | May 04, 2020 | May 05, 2020 |
| BIOVIE INC.BIVI · Entity 7702 | Director | November 20, 2024 | January 07, 2025 |
| COMSovereign Holding Corp.COMS · Entity 114048 | Director | April 01, 2021 | April 06, 2021 |
| Celularity IncCELU · Entity 7145 | Director | December 19, 2024 | January 06, 2025 |
| Context Therapeutics Inc.CNTX · Entity 7406 | Director | June 13, 2024 | June 14, 2024 |
| Cryoport, Inc.CYRX · Entity 5125 | Director | May 17, 2024 | May 21, 2024 |
| Cuentas Inc.CUEN · Entity 8361 | Director | September 13, 2018 | December 21, 2018 |
| Frontier Investment CorpFICV · Entity 111626 | Director | June 30, 2021 | July 12, 2021 |
| LISATA THERAPEUTICS, INC.CLBS · Entity 7814 | Director | January 09, 2017 | January 31, 2017 |
| MetaStat, Inc.MTST.OB · Entity 170270 | Director | April 04, 2017 | April 06, 2017 |
| Ontrak, Inc.OTRK · Entity 78207 | Director | February 11, 2021 | February 16, 2021 |
| Sidus Space Inc.SIDU · Entity 6254 | Director | January 18, 2024 | January 24, 2024 |
| Titan Environmental Solutions Inc.TRIQ · Entity 80360 | Director | April 05, 2021 | April 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ayala Pharmaceuticals, Inc.
Report date May 04, 2020 · Filed May 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2030-05-04 | Direct | 13,000 |
Reported balance
After 2020-05-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-05-04 · Grant · Acquired 13,000 · Balance 13,000 F1: This award relates to an incentive grant awarded by the Compensation Committee and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on May 4, 2021, one-third on May 4, 2022, and will be fully vested on May 4, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: This award relates to an incentive grant awarded by the Compensation Committee and is subject to the terms of our 2015 Incentive Plan. The award vests one-third on May 4, 2021, one-third on May 4, 2022, and will be fully vested on May 4, 2023.
BIOVIE INC.
Report date November 20, 2024 · Filed January 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 40,643 |
Reported balance
After 2024-11-20 transaction · row 1
1 source rowRow 1 · 2024-11-20 · Grant · Acquired 34,200 · Balance 40,643 F1: Represents a restricted stock unit ("RSU") grant, which was approved by the compensation committee of the issuer's board of directors, subject to board approval, which was obtained on November 20, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2029-12-20 | Direct | 23,155 |
Reported balance
After 2024-12-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-20 · Grant · Acquired 23,155 · Balance 23,155 F2: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents a restricted stock unit ("RSU") grant, which was approved by the compensation committee of the issuer's board of directors, subject to board approval, which was obtained on November 20, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting.
F2: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026.
COMSovereign Holding Corp.
Report date April 01, 2021 · Filed April 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.75 · Expires 2026-04-01 | Direct | 225,000 |
Reported balance
After 2021-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-04-01 · Grant · Acquired 225,000 · Balance 225,000 F1: Consists of Stock Option awards made pursuant to the COMS 2020 Long-Term Incentive Plan. F2: The Stock Option awards vest over a two-year period, at a rate of one-half on each anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of Stock Option awards made pursuant to the COMS 2020 Long-Term Incentive Plan.
F2: The Stock Option awards vest over a two-year period, at a rate of one-half on each anniversary of the grant date.
Celularity Inc
Report date December 19, 2024 · Filed January 06, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 67,416 |
Reported balance
After 2024-12-19 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-12-19 · Grant · Acquired 67,416 · Balance 67,416 F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2: Includes 67,416 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.23 · Expires 2034-12-19 | Direct | 202,857 |
Reported balance
After 2024-12-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-12-19 · Grant · Acquired 84,746 · Balance 202,857 F3: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
F2: Includes 67,416 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
F3: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date.
Context Therapeutics Inc.
Report date June 13, 2024 · Filed June 14, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.97 · Expires 2034-06-12 | Direct | 50,000 |
Reported balance
After 2024-06-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-13 · Grant · Acquired 50,000 · Balance 50,000 F1: The option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer.
Cryoport, Inc.
Report date May 17, 2024 · Filed May 21, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 112,845 |
Reported balance
After 2024-05-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-05-17 · Grant · Acquired 12,845 · Balance 112,845 F1: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. |
| Option (Right to Buy Common Stock)SEC Table II · derivative / convertible security · Conversion / exercise price $12.65 · Expires 2031-05-17 | Direct | 23,830 |
Reported balance
After 2024-05-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-05-17 · Grant · Acquired 23,830 · Balance 23,830 F2: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
F2: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024.
Cuentas Inc.
Report date September 13, 2018 · Filed December 21, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Common Stock*SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2023-09-13 | Direct | 30,000 |
Reported balance
After 2018-09-13 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-09-13 · Grant · Acquired 30,000 · Balance 30,000 F1: The 30,000 options to purchase shares of the Issuer's common stock were issued in connection with a grant under the Issuer's 2018 Equity Stock Incentive Plan. F2: 10,000 options are exercisable at 9/13/2018; 10,000 options are exercisable at 9/13/2019; 10,000 options are exercisable at 9/13/2020. |
Filing footnotes · ownership attribution and instrument terms
F1: The 30,000 options to purchase shares of the Issuer's common stock were issued in connection with a grant under the Issuer's 2018 Equity Stock Incentive Plan.
F2: 10,000 options are exercisable at 9/13/2018; 10,000 options are exercisable at 9/13/2019; 10,000 options are exercisable at 9/13/2020.
Frontier Investment Corp
Report date June 30, 2021 · Filed July 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, $0.0001 par valueSEC Table I · non-derivative | IndirectIndirect economic interest for the value of the identified amount of shares. | 31,250 |
Reported balance
Holding disclosure · report date 2021-06-30 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 31,250 |
LISATA THERAPEUTICS, INC.
Report date January 09, 2017 · Filed January 31, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,177 |
Reported balance
After 2017-01-09 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2017-01-09 · Grant · Acquired 1,650 · Balance 7,177 F1: Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018. F2: Includes 2,775 shares of unvested restricted stock granted under the Issuer's compensation plans. |
| Options to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $3.54 · Expires 2027-01-09 | Direct | 2,750 |
Reported balance
After 2017-01-09 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-01-09 · Grant · Acquired 2,750 · Balance 2,750 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents 1,650 shares of restricted stock granted under the Issuer's 2015 Equity Compensation Plan that will vest on January 9, 2018.
F2: Includes 2,775 shares of unvested restricted stock granted under the Issuer's compensation plans.
MetaStat, Inc.
Report date April 04, 2017 · Filed April 06, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,696 |
Reported balance
After 2017-04-04 transaction · row 1
1 source rowRow 1 · 2017-04-04 · Purchase · Acquired 20,000 · Balance 52,696 F1: Reflects the issuance of 20,000 restricted shares of fully vested common stock approved by the board of directors on April 4, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the issuance of 20,000 restricted shares of fully vested common stock approved by the board of directors on April 4, 2017.
Ontrak, Inc.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $86.57 · Expires 2026-02-11 | Direct | 4,882 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 4,882 · Balance 4,882 F1: These securities were granted to Mr. Berman for his services as a member of the Company's Board of Directors and Chairman of the Audit Committee. F2: 1,220 shares shall vest at the end of each quarter beginning January 1, 2021, such that all shares pursuant to the option shall be vested on December 31, 2021. Quarterly vesting of the options will be subject to Mr. Berman attending board meetings, unless such absence is excused by the Chairman of the Board. |
Filing footnotes · ownership attribution and instrument terms
F1: These securities were granted to Mr. Berman for his services as a member of the Company's Board of Directors and Chairman of the Audit Committee.
F2: 1,220 shares shall vest at the end of each quarter beginning January 1, 2021, such that all shares pursuant to the option shall be vested on December 31, 2021. Quarterly vesting of the options will be subject to Mr. Berman attending board meetings, unless such absence is excused by the Chairman of the Board.
Sidus Space Inc.
Report date January 18, 2024 · Filed January 24, 2024
This filing explicitly reported no securities owned.
Titan Environmental Solutions Inc.
Report date April 05, 2021 · Filed April 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 350,000 |
Reported balance
After 2021-04-05 transaction · row 1
1 source rowRow 1 · 2021-04-05 · Grant · Acquired 250,000 · Balance 350,000 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2024 Filed Jan 7, 2025 17:24 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 23,155 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001520138-25-000024 · ownership.xml · derivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,155 Underlying: Common Stock · 23,155 shares Expires 2029-12-20 F2 · derivative.exercise_date: The options vest in three equal installments on December 20, 2024, December 20, 2025 and December 20, 2026. Read SEC document |
| December 19, 2024 Filed Jan 6, 2025 16:54 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option (Right to Buy) · Derivative | 84,746 | $0.00 Strike: $2.23 | $0.00 |
DisclosureSEC source: 0001493152-25-001034 · ownership.xml · derivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,857 Underlying: Class A Common Stock · 84,746 shares Expires 2034-12-19 F3 · derivative.exercise_date: This option was granted under the 2021 Plan and shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| December 19, 2024 Filed Jan 6, 2025 16:54 UTC | Celularity Inc CELU · Entity 7145 | GrantClass A Common Stock | 67,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-001034 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,416 F1 · shares: These shares represent restricted stock units ("RSUs") granted under the Celularity Inc. 2021 Equity Incentive Plan (the "2021 Plan"), with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. F2 · balance_after: Includes 67,416 RSUs granted under the 2021 Plan, with each RSU representing a right to receive one share of the Issuer's Class A common stock. The RSUs shall vest and become exercisable on the earlier of the one-year anniversary of the date of grant, December 19, 2024, and the next annual stockholder meeting, subject to the Reporting Person's continuous service with the Issuer through such date. Read SEC document |
| November 20, 2024 Filed Jan 7, 2025 17:24 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCommon Stock | 34,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-25-000024 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,643 F1 · shares: Represents a restricted stock unit ("RSU") grant, which was approved by the compensation committee of the issuer's board of directors, subject to board approval, which was obtained on November 20, 2024. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments on February 8, 2025, May 8, 2025, August 8, 2025 and the earlier of November 8, 2025 and the date of the issuer's 2025 annual shareholders' meeting. Read SEC document |
| August 27, 2024 Filed Aug 28, 2024 17:26 UTC | Celularity Inc CELU · Entity 7145 | GrantStock Option Grant (Right to Buy) · Derivative | 118,111 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001493152-24-034222 · ownership.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,111 Underlying: Class A Common Stock · 118,111 shares Expires 2034-08-27 F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2021 Equity Incentive Plan. The shares underlying such option will vest in three successive equal annual installments measured from the grant date, subject to the Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 07:41 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $1.97 | $0.00 |
DisclosureSEC source: 0001842952-24-000042 · wk-form4_1718365295.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) June 13, 2025 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2025 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 17, 2024 Filed May 21, 2024 19:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 23,830 | $0.00 Strike: $12.65 | $0.00 |
DisclosureSEC source: 0001104659-24-063961 · tm2415098-1_4seq1.xml · derivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,830 Underlying: Common Stock · 23,830 shares Expires 2031-05-17 F2 · derivative.exercise_date: 1/12th of the options vest on the 17th of the month for twelve months beginning June 17, 2024. Read SEC document |
| May 17, 2024 Filed May 21, 2024 19:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 12,845 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-063961 · tm2415098-1_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,845 F1 · security: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 17, 2025, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 15, 2024 Filed May 16, 2024 17:30 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 8,105 | $13.41 | $108,692.91 |
DisclosureSEC source: 0001104659-24-062629 · tm2414776-1_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.305 to $13.675, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2023 Filed Dec 6, 2023 16:15 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCommon Stock | 51,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-23-000530 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,235 F1 · date: The restricted stock unit ("RSU") grant was approved by the compensation committee of the issuer's board of directors on September 22, 2023, subject to board approval, which was obtained on November 9, 2023. Each RSU represents a contingent right to receive one share of the issuer's Class A common stock. The RSUs vest in four equal installments beginning on February 9, 2024, with the remaining installments vesting on May 9, 2024, August 9, 2024 and the earlier of November 9, 2024 or the date of the issuer's 2024 annual shareholders' meeting. F2 · balance_after: On August 22, 2023, the reporting person filed a Form 4 which inadvertently reported that, following his exercise of an option and sale of the underlying stock, he directly owned 16,789 shares of the issuer's common stock. In fact, as reported in this amendment, the reporting person directly owned 17,405 shares of common stock. Read SEC document |
| August 22, 2023 Filed Aug 24, 2023 20:33 UTC | BIOVIE INC. BIVI · Entity 7702 | SaleCommon Stock | 10,805 | $3.50 | $37,827.22 |
DisclosureSEC source: 0001520138-23-000347 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,789 Read SEC document |
| June 07, 2023 Filed Jun 15, 2023 17:15 UTC | BIOVIE INC. BIVI · Entity 7702 | SaleCommon Stock | 5,984 | $5.81 | $34,782.00 |
DisclosureSEC source: 0001520138-23-000264 · ownership.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,210 Read SEC document |
| May 31, 2023 Filed May 31, 2023 16:52 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $0.87 | $0.00 |
DisclosureSEC source: 0001842952-23-000059 · wf-form4_168556636136177.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-05-30 F1 · derivative.exercise_date: The option vests and becomes exercisable on the earlier of (i) May 31, 2024 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2024 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| May 22, 2023 Filed Jun 15, 2023 17:15 UTC | BIOVIE INC. BIVI · Entity 7702 | SaleCommon Stock | 5,000 | $6.50 | $32,506.00 |
DisclosureSEC source: 0001520138-23-000264 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,194 Read SEC document |
| May 12, 2023 Filed May 16, 2023 19:26 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 15,125 | $0.00 Strike: $20.05 | $0.00 |
DisclosureSEC source: 0001104659-23-061518 · tm2316016-1_4seq1.xml · derivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,125 Underlying: Common Stock · 15,125 shares Expires 2030-05-12 F2 · derivative.exercise_date: 1/12th of the options vest on the 12th of the month for twelve months beginning June 12, 2023. Read SEC document |
| May 12, 2023 Filed May 16, 2023 19:26 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 8,105 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-061518 · tm2316016-1_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,105 F1 · security: Reflects grant of restricted stock rights that vest in full on May 12, 2024, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on May 12, 2024, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| May 11, 2023 Filed May 12, 2023 18:22 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 7,203 | $21.51 | $154,906.28 |
DisclosureSEC source: 0001104659-23-059933 · tm2315733-3_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.39 to $21.68, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 28, 2023 Filed Apr 6, 2023 21:02 UTC | BIOVIE INC. BIVI · Entity 7702 | SaleCOMMON STOCK | 2,613 | $8.52 | $22,262.76 |
DisclosureSEC source: 0001520138-23-000187 · ownership.xml · nonDerivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,194 Read SEC document |
| March 28, 2023 Filed Apr 6, 2023 21:02 UTC | BIOVIE INC. BIVI · Entity 7702 | SaleCOMMON STOCK | 5,000 | $8.52 | $42,607.50 |
DisclosureSEC source: 0001520138-23-000187 · ownership.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,807 Read SEC document |
| March 27, 2023 Filed Apr 6, 2023 21:02 UTC | BIOVIE INC. BIVI · Entity 7702 | SaleCOMMON STOCK | 3,371 | $8.52 | $28,710.81 |
DisclosureSEC source: 0001520138-23-000187 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,807 Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 06:07 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 7,250 | $19.63 | $142,316.05 |
DisclosureSEC source: 0001104659-22-124319 · tm2231929d1_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By spouse Disclosed balance after: 0 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.43 to $19.78, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 23, 2022 Filed Jan 18, 2023 16:22 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantCOMMON STOCK | 43,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001520138-23-000054 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,178 Read SEC document |
| August 16, 2022 Filed Aug 16, 2022 18:29 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 2,708 | $43.05 | $116,588.34 |
DisclosureSEC source: 0001104659-22-091872 · tm2223624-2_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,203 Read SEC document |
| June 02, 2022 Filed Jun 3, 2022 16:09 UTC | Context Therapeutics Inc. CNTX · Entity 7406 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $2.19 | $0.00 |
DisclosureSEC source: 0001842952-22-000058 · wf-form4_165428696068442.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: 1.The option vests and becomes exercisable on the earlier of (i) June 2, 2023 (the one-year anniversary of the date of grant) or (ii) the Issuer's 2023 annual meeting of stockholders, subject to continued service with the Issuer. Read SEC document |
| April 30, 2022 Filed May 3, 2022 20:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionRestricted Stock Rights · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055435 · tm2214402-1_4seq1.xml · derivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. F2 · derivative.expiration_date: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. Read SEC document |
| April 30, 2022 Filed May 3, 2022 20:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 2,708 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-22-055435 · tm2214402-1_4seq1.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Restricted stock rights convert to common stock upon vesting on a one-for-one basis and have no expiration date. Read SEC document |
| April 29, 2022 Filed May 3, 2022 20:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption (Right to Buy Common Stock) · Derivative | 13,981 | $0.00 Strike: $22.56 | $0.00 |
DisclosureSEC source: 0001104659-22-055435 · tm2214402-1_4seq1.xml · derivative · entry 4 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,981 Underlying: Common Stock · 13,981 shares Expires 2029-04-29 F3 · derivative.exercise_date: 1/12th of the options vest on the 30th of the month for twelve months beginning May 30, 2022. Read SEC document |
| April 29, 2022 Filed May 3, 2022 20:00 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantCommon Stock | 7,203 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-055435 · tm2214402-1_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,203 F1 · security: Reflects grant of restricted stock rights that vest in full on April 29, 2023, and upon vesting automatically convert to shares of common stock on a one-for-one basis. F1 · price: Reflects grant of restricted stock rights that vest in full on April 29, 2023, and upon vesting automatically convert to shares of common stock on a one-for-one basis. Read SEC document |
| April 05, 2022 Filed Apr 20, 2022 16:47 UTC | BIOVIE INC. BIVI · Entity 7702 | GrantStock Option (right to buy) · Derivative | 129,050 | $0.00 Strike: $5.04 | $0.00 |
DisclosureSEC source: 0001062993-22-010538 · form4.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,050 Underlying: Common Stock · 129,050 shares Expires 2032-04-05 F1 · security: Options granted pursuant to the Company???s 2019 Omnibus Equity Incentive Plan. F2 · derivative.exercise_date: The options were 25% vested upon grant, with the remaining 75% vesting ratably over a three-year period on each anniversary of the grant date. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 19:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 6,224 | $64.55 | $401,785.96 |
DisclosureSEC source: 0001104659-21-116021 · tm2127766d1_4.xml · nonDerivative · entry 5 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 F5 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.40 to $64.923, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 19:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 15,073 | $64.08 | $965,823.58 |
DisclosureSEC source: 0001104659-21-116021 · tm2127766d1_4.xml · nonDerivative · entry 4 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,224 F4 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.40 to $64.39, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 15, 2021 Filed Sep 15, 2021 19:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | SaleCommon Stock | 3,703 | $62.72 | $232,265.49 |
DisclosureSEC source: 0001104659-21-116021 · tm2127766d1_4.xml · nonDerivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,297 F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.38 to $63.32, inclusive. The reporting person undertakes to provide to Cryoport, Inc., any security holder of Cryoport, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 19:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 10,866 | $0.00 Strike: $18.02 | $0.00 |
DisclosureSEC source: 0001104659-21-116021 · tm2127766d1_4.xml · derivative · entry 7 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,134 Underlying: Common Stock · 10,866 shares Expires 2030-05-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/12 of these options vested and became exercisable on the 1st of each month for twelve (12) months beginning on 06/01/2020. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 19:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 14,134 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001104659-21-116021 · tm2127766d1_4.xml · derivative · entry 6 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,134 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/12 of these options vested and became exercisable on the 1st of each month for twelve (12) months beginning on 05/02/2019. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 19:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 10,866 | $18.02 | $195,805.32 |
DisclosureSEC source: 0001104659-21-116021 · tm2127766d1_4.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2021 Filed Sep 15, 2021 19:09 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 14,134 | $14.35 | $202,822.90 |
DisclosureSEC source: 0001104659-21-116021 · tm2127766d1_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 30, 2021 Filed May 7, 2021 18:42 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantRestricted Stock Rights · Derivative | 2,708 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-063249 · tm2115610d2_4.xml · derivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,708 Underlying: Common Stock · 2,708 shares Expires 2022-04-30 F2 · derivative.exercise_price: Each restricted stock right represents a contingent right to receive one share of CYRX common stock. Read SEC document |
| April 30, 2021 Filed May 7, 2021 18:42 UTC | Cryoport, Inc. CYRX · Entity 5125 | GrantOption to purchase common stock · Derivative | 5,416 | $0.00 Strike: $56.57 | $0.00 |
DisclosureSEC source: 0001104659-21-063249 · tm2115610d2_4.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,416 Underlying: Common Stock · 5,416 shares Expires 2028-04-30 F1 · derivative.exercise_date: 1/12th of options vest on the 30th of the month for twelve months beginning May 30, 2021. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 19:23 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 6,923 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001104659-21-048985 · tm2112685-1_4seq1.xml · derivative · entry 4 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,923 shares Expires 2028-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/12th of the 35,000 options originally granted vested on the 17th of the month for twelve months beginning on June 17, 2018. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 19:23 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 20,866 | $0.00 Strike: $14.35 | $0.00 |
DisclosureSEC source: 0001104659-21-048985 · tm2112685-1_4seq1.xml · derivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,134 Underlying: Common Stock · 20,866 shares Expires 2029-05-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/12th of the 35,000 options originally granted vested on the 2nd of the month for twelve months beginning on June 2, 2019. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 19:23 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 20,866 | $14.35 | $299,427.10 |
DisclosureSEC source: 0001104659-21-048985 · tm2112685-1_4seq1.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 07, 2021 Filed Apr 9, 2021 19:23 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 6,923 | $9.29 | $64,314.67 |
DisclosureSEC source: 0001104659-21-048985 · tm2112685-1_4seq1.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 17:05 UTC | Titan Environmental Solutions Inc. TRIQ · Entity 80360 | GrantCommon stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-21-008116 · ownership.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,000 Read SEC document |
| April 01, 2021 Filed Apr 6, 2021 12:48 UTC | COMSovereign Holding Corp. COMS · Entity 114048 | GrantStock Options (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001213900-21-020330 · ownership.xml · derivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2026-04-01 F1 · security: Consists of Stock Option awards made pursuant to the COMS 2020 Long-Term Incentive Plan. F2 · derivative.exercise_date: The Stock Option awards vest over a two-year period, at a rate of one-half on each anniversary of the grant date. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 16:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 28,077 | $0.00 Strike: $9.29 | $0.00 |
DisclosureSEC source: 0001104659-21-041552 · tm2110964d1_4.xml · derivative · entry 6 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,923 Underlying: Common Stock · 28,077 shares Expires 2028-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 1/12 of the 35,000 options originally granted vested on the 17th of the month for twelve months beginning on June 17, 2018. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 16:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 18,885 | $0.00 Strike: $4.80 | $0.00 |
DisclosureSEC source: 0001104659-21-041552 · tm2110964d1_4.xml · derivative · entry 5 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,115 shares Expires 2027-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 1/12 of the 35,000 options originally granted vested on the 23rd of the month for twelve months beginning on July 23, 2017. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 16:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionOptions to purchase common stock · Derivative | 4,167 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001104659-21-041552 · tm2110964d1_4.xml · derivative · entry 4 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,167 shares Expires 2025-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 1/12 of the 50,000 options originally granted vested on the 12th of the month for twelve months beginning on June 7, 2015. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 16:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 28,077 | $9.29 | $260,835.33 |
DisclosureSEC source: 0001104659-21-041552 · tm2110964d1_4.xml · nonDerivative · entry 3 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 16:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 18,885 | $4.80 | $90,648.00 |
DisclosureSEC source: 0001104659-21-041552 · tm2110964d1_4.xml · nonDerivative · entry 2 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 24, 2021 Filed Mar 25, 2021 16:47 UTC | Cryoport, Inc. CYRX · Entity 5125 | Exercise / conversionCommon Stock | 4,167 | $7.80 | $32,502.60 |
DisclosureSEC source: 0001104659-21-041552 · tm2110964d1_4.xml · nonDerivative · entry 1 BERMAN RICHARD J · CIK 0001111620 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.